Forbes January 14, 2026
In this week’s edition of InnovationRx, we look at upcoming M&A activity, a ‘holy grail’ pill for sleep apnea, Pomelo Care’s expansion, Nvidia and Lilly’s $1 billion AI venture, and more.
This week kicked off the healthcare industry’s yearly extravaganza: The 44th annual J.P. Morgan Healthcare Conference, which is typically a hotbed of dealmaking activity.
This year, the M&A talk ahead of the San Francisco event was relatively muted. Lilly agreed last week to buy Ventyx, which is working on a drug to treat recurrent pericarditis, for $1.2 billion. But while there were no megadeal announcements, the potential for one lurked in the background. On Thursday, the Financial Times reported that Merck was in talks to buy cancer drug developer...
Today's Sponsors
Today's Sponsor